

Georges H Mairesse

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3475358/publications.pdf>

Version: 2024-02-01

8
papers

1,650
citations

1478505

6
h-index

1588992

8
g-index

8
all docs

8
docs citations

8
times ranked

2265
citing authors

#	ARTICLE	IF	CITATIONS
1	Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. <i>Circulation</i> , 2014, 129, 2094-2099.	1.6	579
2	Screening for Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 1851-1867.	1.6	453
3	Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. <i>American Heart Journal</i> , 2017, 189, 137-145.	2.7	258
4	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulaci3n Cardaca y Electrofisiologaa (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	1.7	208
5	Estimated stroke risk, yield, and number needed to screen for atrial fibrillation detected through single time screening: a multicountry patient-level meta-analysis of 141,220 screened individuals. <i>PLoS Medicine</i> , 2019, 16, e1002903.	8.4	90
6	A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. <i>Europace</i> , 2016, 18, euw069.	1.7	55
7	Consumer-led screening for atrial fibrillation: What is the next step?. <i>European Journal of Internal Medicine</i> , 2021, 90, 16-18.	2.2	5
8	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. <i>Acta Cardiologica</i> , 2021, 76, 431-439.	0.9	2